Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: AZD6738 for Patients With Progressive MDS or CMML [Phase 1]
Phase 1 clinical trial update of AZD6738 in patients with progressive myelodysplastic syndrome or chronic myelomonocytic leukemia; the study…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: A Long Term Follow-up Study of TScan TCR-T Products
This clinical trial update describes a long-term follow-up study of TScan Therapeutics' TCR-T cell therapies for acute myeloid leukemia, acu…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Cord Blood Transplant in Adults With Blood Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant in adults with blood cancers is currently recruiting. Conditions include acute myeloid leukem…
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation [Phase 2]
Phase 2 clinical trial evaluating treosulfan versus melphalan conditioning followed by post-transplant cyclophosphamide in AML and MDS patie…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes [Phase 2]
Phase 2 trial update evaluating the infusion of expanded cord blood cells in addition to a single cord blood transplant for patients with ac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions [NA]
Feasibility and safety of exercise in patients with low-risk myeloid cancers and precursor conditions are being studied in this clinical tri…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [Phase 2]
This clinical trial update describes a Phase 2 study evaluating TCRγδ T cells and memory T cells with selective use of blinatumomab as part …
-
CLINICAL_TRIALS research · 2025-08-05Clinical Trial Update: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome [Phase 3]
Phase 3 clinical trial evaluating venetoclax with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome. The study is current…
-
CLINICAL_TRIALS research · 2025-07-30Clinical Trial Update: Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation [Phase 1]
This document provides an update on a Phase 1 trial evaluating maintenance therapy with selinexor and azacitidine in patients with TP53-muta…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Reduced Intensity Conditioning for MDS [Phase 2]
Phase 2 trial evaluating reduced intensity conditioning for myelodysplastic syndrome; the study is currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-07-11Clinical Trial Update: Administration of Donor T Cells With the Caspase-9 Suicide Gene [Phase 1]
A Phase 1 trial evaluating donor T cells engineered with a caspase-9 suicide gene to enable controlled safety in hematologic diseases.
-
CLINICAL_TRIALS research · 2025-07-08Clinical Trial Update: 90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 clinical trial of a radiolabeled anti-CD25 antibody with fludarabine, melphalan, and total marrow and lymphoid irradiation for high-…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning [Phase 2]
Phase 2 trial evaluating vedolizumab with post-transplant cyclophosphamide and tacrolimus to prevent graft-versus-host disease in patients u…
-
CLINICAL_TRIALS research · 2025-06-05Clinical Trial Update: Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation [Phase 2]
This Phase 2 trial investigates HPV vaccination in recipients of allogeneic stem cell transplantation and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant [Phase 1]
Phase 1 trial evaluating emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil to prevent graft-versus-host…
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants [Phase 2]
Phase 2 clinical trial update describing the addition of itacitinib to cyclophosphamide and tacrolimus for preventing graft-versus-host dise…
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS [Phase 2]
This clinical trial update describes a Phase 2 study evaluating palliative care oncology in adults with relapsed, refractory, or high-risk a…
-
CLINICAL_TRIALS research · 2025-05-11Clinical Trial Update: ATG Plus PTCy vs ATG for CGVHD Prophylaxis [Phase 2]
Phase 2 trial comparing ATG plus post-transplant cyclophosphamide versus ATG for prophylaxis of chronic graft-versus-host disease in patient…
-
CLINICAL_TRIALS research · 2025-04-17Clinical Trial Update: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial [Phase 2]
Phase 2 trial evaluating fecal microbiota transplantation before allogeneic stem cell transplant; recruitment is ongoing across multiple hem…
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) [Phase 1]
Phase 1 clinical trial assessing a preventive therapy to reduce graft-versus-host disease in participants with hematologic malignancies unde…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients [Phase 2]
Phase 2 clinical trial evaluating selinexor in combination with azacitidine for high-risk myeloid neoplasms, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-03-04Clinical Trial Update: A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies [Phase 1]
Phase 1 study of XS-04 in relapsed or refractory hematologic malignancies, including B-cell lymphoma, acute myeloid leukemia, and myelodyspl…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: Blood Samples to Identify Biomarkers of Busulfan
A terminated clinical trial at Fred Hutchinson Cancer Center investigated using blood samples to identify biomarkers of busulfan exposure. T…
-
CLINICAL_TRIALS research · 2025-03-03Clinical Trial Update: A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic Syndrome [Phase 1, Phase 2]
Akeso's AK117 (anti-CD47) is in a Phase 1/2 clinical trial for myelodysplastic syndrome and the study is currently active but not recruiting…
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes [Phase 2]
A Phase 2 study evaluating AK117 in combination with azacitidine for higher-risk myelodysplastic syndromes is currently recruiting.